How to Help Your Patients Save Money on Zurzuvae: A Provider's Guide to Savings Programs

With a wholesale acquisition cost of approximately $15,900 for a 14-day treatment course, the cost of Zurzuvae (zuranolone) is one of the most significant barriers to treatment for your postpartum depression patients. But a robust set of financial assistance programs exists to bridge this gap—and navigating them effectively is something providers and care teams can directly influence.

This guide covers every savings pathway available in 2026, eligibility requirements, how to access each program, and strategies to minimize patient cost and maximize treatment access.

The Cost Landscape: What Patients Actually Pay

The key message for patients: the list price is almost never the price they pay. Approximately 95% of commercially insured and Medicaid patients have some form of Zurzuvae coverage. The three largest PBMs include Zurzuvae on formulary. The real challenge is not whether coverage exists—but navigating prior authorization, step therapy, and tier placement.

Program 1: The Zurzuvae Savings Card (Commercial Insurance)

This is the most impactful financial assistance option for commercially insured patients. The Zurzuvae Savings Card Program, administered through Sage Therapeutics, can reduce patient cost to

$0 for a 14-day supply.

Provider actions:

• Refer patients to Sage Central (1-844-987-9882) to enroll in the savings card at the time of prescribing—not after they're already struggling with bills
• Confirm with Sage Central whether the specific specialty pharmacy your patient will use applies the savings card automatically at the time of dispensing
• Advise patients that the savings card is applied by the specialty pharmacy—not like a standard coupon they print out

Eligibility requirements:

• Commercial insurance only (not Medicare, Medicaid, VA, TRICARE, or other government programs)
• U.S. resident
• Restrictions apply—direct patients to Sage Central for current terms and conditions

Program 2: Patient Assistance Program (Uninsured / Underinsured)

For patients who are uninsured or underinsured and who would otherwise face the full list price, Sage Therapeutics offers a free drug program through Sage Central. This program provides Zurzuvae at no charge to eligible patients who meet income and insurance status criteria.

Provider actions:

• Ask Sage Central specifically about the "free drug program" when calling on behalf of uninsured patients
• Prepare the patient to provide income documentation and proof of lack of insurance coverage
• Initiate this process as early as possible—before the prescription is submitted—to minimize delays

Program 3: Medicaid Coverage Navigation

Zurzuvae is covered by many state Medicaid programs, but coverage varies significantly by state. Some states have aggressive step therapy requirements; others have added Zurzuvae directly to their formularies with minimal restrictions.

Provider actions:

• Confirm your state's Medicaid formulary status for Zurzuvae before submitting the prescription
• If step therapy applies, document any prior antidepressant failures thoroughly in the PA—including specific medications, doses, durations, and reasons for inadequacy
• Sage Central can assist with Medicaid coverage verification and PA support for Medicaid patients

39,049+ patients found their medications in stock

39K+

Find Zurzuvae In Stock Today →

Program 4: Medicare (Special Considerations)

Zurzuvae is typically listed on Tier 5 (specialty tier) of Medicare Part D formularies, which carries the highest cost-sharing. The manufacturer savings card cannot be used for Medicare patients. Options include:

• Low Income Subsidy (LIS / Extra Help): Medicare beneficiaries who qualify for Extra Help pay significantly reduced cost-sharing for specialty drugs. Help patients apply through SSA or their State Health Insurance Assistance Program (SHIP).
• Medicare Advantage formulary exception: Submit a formulary exception request with a letter of medical necessity if Zurzuvae is not on your patient's plan formulary.

Strategy: Writing Effective Prior Authorizations and Appeals

The prior authorization is your most powerful tool for removing financial barriers. Key elements of an effective PA:

• Use F53.0: The ICD-10 code for postpartum depression. This is essential—using a generic MDD code may trigger denial.
• Document severity: Include HAMD-17 or EPDS scores, symptom onset timing, and impact on maternal functioning and infant bonding.
• Invoke rapid onset: For step therapy cases, document the medical necessity of Zurzuvae's GABA-targeting mechanism and Day 3 onset—qualities that SSRIs (which take 2-4 weeks) cannot provide for acute, severe PPD.
• Document prior treatment failures: If step therapy applies, list prior antidepressants with specific doses, durations, and reasons for failure or discontinuation.
• Address breastfeeding constraints: Note any clinical reasons why SSRI alternatives may not be appropriate (e.g., the patient is not breastfeeding and requests PPD-specific therapy).

Skip the calls, skip the stress.

Find Zurzuvae In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Key Resources for Providers

Sage Central: 1-844-987-9882 | Benefits investigation, PA support, savings enrollment, free drug program access. medfinder for providers: medfinder.com/providers | Identify which specialty pharmacies in your patient's area can fill Zurzuvae prescriptions. CoverMyMeds: Streamline PA submissions across all payers.